There is a reason sarcoma is called the forgotten cancer, and the funding figures state it about as plainly as figures can. Breast cancer research receives roughly $930 million a year from the National Cancer Institute, while the entire federal Rare Cancers Research Program, which covers all rare cancers together rather than sarcoma alone, received about $17.5 million. This is not an argument against breast cancer funding, which does enormous good; it is an argument about proportion, because set those two numbers side by side and the gap is staggering, with a single common cancer commanding more than fifty times the dedicated research money of every rare cancer combined. Sarcoma, one of dozens of rare cancers, is left fighting for a sliver of that sliver.
Remember why, from earlier this month. Research dollars follow patient numbers, and sarcoma is fractured into more than seventy subtypes, each too small on its own to command sustained attention, so the very rarity that makes it hard to diagnose and hard to treat also makes it easy to overlook when budgets are set. The forgotten cancer is forgotten at every level, including the one where future treatments are funded, and that underfunding is not abstract: it means fewer new drugs, fewer clinical trials, slower progress, and, for patients today, a thinner menu of options than common cancers enjoy. When you hear that a sarcoma has “limited treatment options,” this budget is part of the reason why.
Here is the part worth holding onto, though. Awareness is not separate from funding; public attention drives research dollars, and the reason breast cancer research is so well funded is, in part, decades of relentless and genuinely successful awareness. That is why a month like this one matters beyond sentiment, because visibility sits upstream of money and money sits upstream of cures. So this is the single post this month that asks something of the wider world rather than the patient: make sarcoma harder to forget. Share it, and say its name, because the budget tends to follow the spotlight.